Comparative efficacy of escitalopram in the treatment of major depressive disorder

Neuropsychiatric Disease and Treatment

Volumn 7, Issue 1, 2011, Pages 39-49

  Ali, Mazen K ^a   Lam, Raymond W ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Antidepressants; Depressive disorders; Efficacy; Escitalopram; Meta analysis; Pooled analysis

Indexed keywords

AMFEBUTAMONE; CITALOPRAM; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; MILNACIPRAN; MIRTAZAPINE; NEFAZODONE; PAROXETINE; REBOXETINE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRAZODONE; VENLAFAXINE;

ARTICLE; DRUG EFFICACY; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EFFECT SIZE; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; META ANALYSIS; MONTGOMERY ASBERG DEPRESSION RATING SCALE; RANDOMIZED CONTROLLED TRIAL; REMISSION; SYSTEMATIC REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 79951635783     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S12531     Document Type: Article

References (55)

1. Patten SB, Kennedy SH, Lam RW, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical Guidelines for the Management of Major Depressive Disorder in Adults. I. Classification, burden and principles of management. J Affect Disord. 2009; 117 Suppl 1: S5-S14.
2. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006; 3:e442.
3. Stephens T, Joubert N. The economic burden of mental health problems in Canada. Chronic Dis Can. 2001; 22:18-23.
4. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: How did it change between 1990 and 2000? J Clin Psychiatry. 2003; 64:1465-1475.
5. Sobocki P, Jonsson B, Angst J, Rehnberg C. Cost of depression in Europe. J Ment Health Policy Econ. 2006; 9:87-98.
6. Davidson JR. Major depressive disorder treatment guidelines in America and Europe. J Clin Psychiatry. 2010; 71 Suppl E1:e04.
7. Lam RW, Kennedy SH, Grigoriadis S, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. III. Pharmacotherapy. J Affect Disord. 2009; 117 Suppl 1:S26-S43.
8. Anderson IM, Ferrier IN, Baldwin RC, et al. Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2000 British Association for Psychopharmacology guidelines. J Psychopharmacol. 2008; 22:343-396.
9. Sanchez C. The pharmacology of citalopram enantiomers: The antagonism by R-citalopram on the effect of S-citalopram. Basic Clin Pharmacol Toxicol. 2006; 99:91-95.
10. Thase ME. Managing depressive and anxiety disorders with escitalopram. Expert Opin Pharmacother. 2006; 7:429-440.
11. Waugh J, Goa KL. Escitalopram: A review of its use in the management of major depressive and anxiety disorders. CNS Drugs. 2003; 17: 343-362.
12. Montgomery SA, Baldwin DS, Blier P, et al. Which antidepressants have demonstrated superior efficacy? A review of the evidence. Int Clin Psychopharmacol. 2007; 22:323-329.
13. Baldwin DS, Reines EH, Guiton C, Weiller E. Escitalopram therapy for major depression and anxiety disorders. Ann Pharmacother. 2007; 41:1583-1592.
14. Lieberman JA, Greenhouse J, Hamer RM, et al. Comparing the effects of antidepressants: Consensus guidelines for evaluating quantitative reviews of antidepressant efficacy. Neuropsychopharmacology. 2005; 30:445-460.
15. Lam RW, Kennedy SH. Using metaanalysis to evaluate evidence: Practical tips and traps. Can J Psychiatry. 2005; 50:167-174.
16. Kennedy SH, Andersen HF, Thase ME. Escitalopram in the treatment of major depressive disorder: A meta-analysis. Curr Med Res Opin. 2009; 25:161-175.
17. Kennedy SH, Andersen HF, Lam RW. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: A meta-analysis. J Psychiatry Neurosci. 2006; 31:122-131.
18. Lam RW, Lonn SL, Despiegel N. Escitalopram versus serotonin noradrenaline reuptake inhibitors as second step treatment for patients with major depressive disorder: A pooled analysis. Int Clin Psychopharmacol. 2010; 25:199-203.
19. Wade AG, Schlaepfer TE, Andersen H F, Kilts CD. Clinical milestones predict symptom remission over 6-month and choice of treatment of patients with major depressive disorder (MDD). J Psychiatr Res. 2009; 43:568-575.
20. Kasper S, Spadone C, Verpillat P, Angst J. Onset of action of escitalopram compared with other antidepressants: Results of a pooled analysis. Int Clin Psychopharmacol. 2006; 21:105-110.
21. Papakostas GI, Larsen K. Testing anxious depression as a predictor and moderator of symptom improvement in major depressive disorder during treatment with escitalopram. Eur Arch Psychiatry Clin Neurosci. 2010 Sep 22. [Epub ahead of print]
22. Wade A, Friis AH. The onset of effect for escitalopram and its relevance for the clinical management of depression. Curr Med Res Opin. 2006; 22:2101-2110.
23. Gorman JM, Korotzer A, Su G. Efficacy comparison of escitalopram and citalopram in the treatment of major depressive disorder: Pooled analysis of placebo-controlled trials. CNS Spectr. 2002; 7:40-44.
24. Kilts CD, Wade AG, Andersen HF, Schlaepfer TE. Baseline severity of depression predicts antidepressant drug response relative to escitalopram. Expert Opin Pharmacother. 2009; 10:927-936.
25. Lam RW, Andersen H F. The influence of baseline severity on efficacy of escitalopram and citalopram in the treatment of major depressive disorder: An extended analysis. Pharmacopsychiatry. 2006; 39:180-184.
26. Bech P, Andersen HF, Wade A. Effective dose of escitalopram in moderate versus severe DSM-IV major depression. Pharmacopsychiatry. 2006; 39:128-134.
27. Llorca PM, Azorin JM, Despiegel N, Verpillat P. Efficacy of escitalopram in patients with severe depression: A pooled analysis. Int J Clin Pract. 2005; 59:268-275.
28. Lepola U, Wade A, Andersen H F. Do equivalent doses of escitalopram and citalopram have similar efficacy? A pooled analysis of two positive placebo-controlled studies in major depressive disorder. Int Clin Psychopharmacol. 2004; 19:149-155.
29. Clayton AH, Croft HA, Horrigan J P, et al. Bupropion extended release compared with escitalopram: Effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies. J Clin Psychiatry. 2006; 67:736-746.
30. Auquier P, Robitail S, Llorca PM, Rive B. Comparison of escitalopram and citalopram efficacy: A meta-analysis. Int J Psychiatry Clin Pract. 2003; 7:259-268.
31. Soares CN, Thase ME, Clayton A, et al. Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder. Menopause. 2010; 17:700-711.
32. Kasper S, Baldwin DS, Larsson LS, Boulenger J P. Superiority of escitalopram to paroxetine in the treatment of depression. Eur Neuropsychopharmacol. 2009; 19:229-237.
33. Montgomery SA, Andersen HF. Escitalopram versus venlafaxine XR in the treatment of depression. Int Clin Psychopharmacol. 2006; 21:297-309.
34. Lam RW, Andersen HF, Wade AG. Escitalopram and duloxetine in the treatment of major depressive disorder: A pooled analysis of two trials. Int Clin Psychopharmacol. 2008; 23:181-187.
35. Kornstein SG, Li D, Mao Y, Larsson S, Andersen HF, Papakostas GI. Escitalopram versus SNRI antidepressants in the acute treatment of major depressive disorder: Integrative analysis of four double-blind, randomized clinical trials. CNS Spectr. 2009; 14:326-333.
36. Cipriani A, Santilli C, Furukawa TA, et al. Escitalopram versus other antidepressive agents for depression. Cochrane Database Syst Rev. 2009; CD006532.
37. Gartlehner G, Gaynes BN, Hansen RA, et al. Comparative benefits and harms of second-generation antidepressants: Background paper for the American College of Physicians. Ann Intern Med. 2008; 149:734-750.
38. Trkulja V. Is escitalopram really relevantly superior to citalopram in treatment of major depressive disorder? A meta-analysis of head-to-head randomized trials. Croat Med J. 2010; 51:61-73.
39. Montgomery S, Hansen T, Kasper S. Efficacy of escitalopram compared with citalopram: A meta-analysis. Int J Neuropsychopharmacol. 2010: 1-8.
40. Salanti G, Higgins J P, Ades AE, Ioannidis J P. Evaluation of networks of randomized trials. Stat Methods Med Res. 2008; 17:279-301.
41. Lumley T. Network meta-analysis for indirect treatment comparisons. Stat Med. 2002; 21:2313-2324.
42. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 12 new-generation antidepressants: A multiple-treatments meta-analysis. Lancet. 2009; 373:746-758.
43. Duru G, Fantino B. The clinical relevance of changes in the Montgomery-Asberg Depression Rating Scale using the minimum clinically important difference approach. Curr Med Res Opin. 2008; 24:1329-1335.
44. Montgomery SA, Moller HJ. Is the significant superiority of escitalopram compared with other antidepressants clinically relevant? Int Clin Psychopharmacol. 2009; 24:111-118.
45. Boulenger J P, Huusom AK, Florea I, Baekdal T, Sarchiapone M. A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients. Curr Med Res Opin. 2006; 22:1331-1341.
46. Moore N, Verdoux H, Fantino B. Prospective, multi centre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder. Int Clin Psychopharmacol. 2005; 20:131-137.
47. Chen F, Larsen MB, Neubauer HA, Sanchez C, Plenge P, Wiborg O. Characterization of an allosteric citalopram-binding site at the serotonin transporter. J Neurochem. 2005; 92:21-28.
48. Sanchez C, Bogeso K P, Ebert B, Reines EH, Braestrup C. Escitalopram versus citalopram: The surprising role of the R-enantiomer. Psychopharmacolog y (Berl). 2004; 174:163-176.
49. El Mansari M, Sanchez C, Chouvet G, Renaud B, Haddjeri N. Effects of acute and long-term administration of escitalopram and citalopram on serotonin neurotransmission: An in vivo electrophysiological study in rat brain. Neuropsychopharmacology. 2005; 30:1269-1277.
50. Mnie-Filali O, El Mansari M, Espana A, Sanchez C, Haddjeri N. Allosteric modulation of the effects of the 5-HT reuptake inhibitor escitalopram on the rat hippocampal synaptic plasticity. Neurosci Lett. 2006; 395:23-27.
51. Mnie-Filali O, Faure C, Mansari ME, et al. R-citalopram prevents the neuronal adaptive changes induced by escitalopram. Neuroreport. 2007; 18:1553-1556.
52. Storustovu S, Sanchez C, Porzgen P, et al. R-citalopram functionally antagonises escitalopram in vivo and in vitro: Evidence for kinetic interaction at the serotonin transporter. Br J Pharmacol. 2004; 142:172-180.
53. Chen F, Larsen MB, Sanchez C, Wiborg O. The S-enantiomer of R, S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors. Eur Neuropsychopharmacol. 2005; 15:193-198.
54. Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: A meta-analysis. J Clin Psychopharmacol. 2009; 29: 259-266.
55. Lancon C, Sapin C, Note I, Farisse J. Comparison of escitalopram and citalopram in outpatients with severe major depressive disorder: A prospective, naturalistic 8-week study. Int J Psychiatry Clin Pract. 2006; 10:131-137.